ECSP066495A - Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv) - Google Patents

Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)

Info

Publication number
ECSP066495A
ECSP066495A ECSP066495A ECSP066495A EC SP066495 A ECSP066495 A EC SP066495A EC SP066495 A ECSP066495 A EC SP066495A EC SP066495 A ECSP066495 A EC SP066495A
Authority
EC
Ecuador
Prior art keywords
wssv
white point
compositions
syndrome virus
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Kurt R Klimpel
Original Assignee
Aqua Bounty Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqua Bounty Technologies Inc filed Critical Aqua Bounty Technologies Inc
Publication of ECSP066495A publication Critical patent/ECSP066495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/18011—Nimaviridae
    • C12N2710/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/18011—Nimaviridae
    • C12N2710/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona a una composición novedosa útil para inhibir la infección causada por el Virus del Síndrome de punto blanco (WSSV) de animales crustáceos, partcularmente aquellos del género Penaeus, sp. Más específicamente, la composición novedosa comprende un polipéptido cuya secuencia de aminoacidos corresponde al menos a una porción de Vp28, una proteína de superficie del WSSV, o un anticuerpo que se algutina específicamente al polipéptido. También se describen las secuencias de polinuceótidos que codifican para los polipéptidos Vp`28 de la presente invención. El descubrimiento además incluye métodos para usar las composiciones novedosas para inhibir la infección causada por WSSV em animales crustáceos.
ECSP066495 2003-09-09 2006-04-07 Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv) ECSP066495A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50161403P 2003-09-09 2003-09-09

Publications (1)

Publication Number Publication Date
ECSP066495A true ECSP066495A (es) 2006-11-24

Family

ID=34273061

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP066495 ECSP066495A (es) 2003-09-09 2006-04-07 Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)

Country Status (10)

Country Link
US (1) US20070059808A1 (es)
EP (1) EP1664268A4 (es)
CN (1) CN101166752A (es)
AU (1) AU2004271211A1 (es)
BR (1) BRPI0414157A (es)
CA (1) CA2537995A1 (es)
EC (1) ECSP066495A (es)
MX (1) MXPA06002730A (es)
WO (1) WO2005023992A2 (es)
ZA (1) ZA200602871B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148166A1 (en) * 2002-05-13 2007-06-28 Wu Madeline C S Scfvs in photosynthetic microbes
CN102046650A (zh) * 2008-06-20 2011-05-04 瓦赫宁恩大学 感染抑制剂
CN101691403B (zh) * 2009-08-03 2011-11-09 中国海洋大学 抗对虾白斑症病毒囊膜蛋白vp28独特型单克隆抗体及其制备方法
CN101919873B (zh) * 2010-07-16 2011-05-04 韩健宝 抗wssv和/或tsv的核酸药物
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
BR112013010288A2 (pt) 2010-10-27 2016-09-20 Harrisvaccines Inc método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
MY161995A (en) * 2010-11-10 2017-05-31 Univ Malaya Vaccine against white spot syndrome virus
MY153741A (en) 2010-11-10 2015-03-13 Univ Malaya A method for producing bio-active agent for the prevention of disease caused by white spot syndrome baculovirus complex and a bio-active agent derived thereof
CN103766626B (zh) * 2012-10-22 2015-05-06 中国科学院海洋研究所 一种预防对虾白斑病的饲料添加剂及其制备方法
CN107881258A (zh) * 2017-11-14 2018-04-06 上海海洋大学 Vp53b基因及蛋白在制备防治对虾白斑综合征的药物中的应用
CN109517037B (zh) * 2018-10-31 2022-02-08 青岛科技大学 具有白斑综合征病毒抑制作用的多肽及其应用
CN109673869A (zh) * 2018-12-27 2019-04-26 南京瑞碧斯生物科技有限公司 一种修复免疫抗应激能力的虾蟹饵料及其应用
KR102330545B1 (ko) * 2019-11-18 2021-11-29 (주)애드바이오텍 새우 폐사 방지용 난황항체의 제조방법
CN112094853A (zh) * 2020-09-24 2020-12-18 扬州大学 白斑综合征病毒vp28基因、重组蛋白、多克隆抗体及制备方法和应用
CN114875035B (zh) * 2022-04-25 2024-11-22 闽江学院 一种凡纳滨对虾溶质转运基因LvSLC5A8及其编码蛋白和应用
CN118530375B (zh) * 2024-07-26 2024-11-05 山东省动物疫病预防与控制中心(山东省人畜共患病流调监测中心) 一种白斑综合征病毒的多表位融合蛋白、抗体、编码基因和重组质粒以及它们的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60024100D1 (de) * 1999-08-03 2005-12-22 Akzo Nobel Nv Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
CN1303942A (zh) * 1999-11-24 2001-07-18 国家海洋局第三海洋研究所 对虾白斑杆状病毒基因组DNA序列及c DNA序列
WO2001098335A2 (en) * 2000-06-20 2001-12-27 Phycotransgenics, Llc Transgenic algae for delivering antigens to an animal
WO2003000900A1 (en) * 2001-06-22 2003-01-03 Akzo Nobel N.V. White spot syndrome virus vaccine

Also Published As

Publication number Publication date
WO2005023992A2 (en) 2005-03-17
WO2005023992A3 (en) 2007-07-05
AU2004271211A1 (en) 2005-03-17
ZA200602871B (en) 2008-07-30
EP1664268A2 (en) 2006-06-07
EP1664268A4 (en) 2008-09-03
US20070059808A1 (en) 2007-03-15
CA2537995A1 (en) 2005-03-17
BRPI0414157A (pt) 2006-10-31
CN101166752A (zh) 2008-04-23
MXPA06002730A (es) 2006-09-04

Similar Documents

Publication Publication Date Title
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
NO20075927L (no) IL-21 varianter
UY28250A1 (es) Composiciones farmacéuticas para inhibidores de la proteasa del virus de la hepatitis c
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
BRPI0510527A (pt) método de estabilização de proteìnas
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
ATE549028T1 (de) Stabile analoga von glp-1
NO20044897L (no) Hepatitt C virus inhibitorer
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
CO5700785A2 (es) Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
CO2021017664A2 (es) Péptidos
EP1548107A4 (en) CHROMOPROTEIN AND FLUORO PROTEINS
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
BRPI0401908A (pt) Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses
NO20063521L (no) Blandinger, fremgangsmater og anvendelser av en ny peptidfamilie
BRPI0606445A2 (pt) inibidores de hipersecreÇço de mucina e mÉtodos de uso
DK1949913T3 (da) Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C